Jaclyn Tilak

Jaclyn’s representative work includes acting for:

• Takeda Canada v Apotex, 2024 FC 106 - Counsel to Apotex in the successful dismissal of a patent proceeding relating to the drug dexlansoprazole (used to treat heartburn), on the basis of invalidity and non-infringement.
• AbbVie Corporation v. JAMP Pharma Corporation, 2022 FC 1209 – successful representation of JAMP in a judicial review application resulting in JAMP retaining its Notice of Compliance for its adalimumab product
• Steelhead v. ARC Resources, 2022 FC 998 – successful representation of four defendants in a summary trial dismissing an action for alleged patent infringement
• Teva Canada Innovation v. Pharmascience, 2020 FC 1158 – successful challenge to the validity of a patent related to a multiple sclerosis medication, on the basis of obviousness
• Eli Lilly v. Apotex, 2020 FC 816 – successful challenge to the validity and infringement of a patent relating to the dose of an ED medication, on the bases of anticipation and obviousness
• Eli Lilly v. Apotex, 2020 FC 814 – successful challenge to the validity and infringement of a patent relating to the process to make the active ingredient in an ED medication, on the bases of anticipation and obviousness
• Evolution Technologies v. Human Care Canada, 2019 FCA 209 – successful appeal of a trial judgment enjoining the sale of a major mobility-aid product and awarding financial remedies on account of patent infringement
• Evolution Technologies v. Human Care Canada, 2019 FCA 11 – successful motion to stay a trial judgment enjoining the sale of a major mobility-aid product and awarding financial remedies, pending the outcome of an appeal